Tradeoffs

Twenty-six states have passed bans on gender-affirming care for transgender minors, and the Supreme Court is set to hear arguments in December about Tennessee's ban. We take a closer look at gender-affirming care and the legal arguments that could influence how accessible that care is.Meredithe McNamara, MD, Assistant Professor of Pediatrics, Yale School of MedicineKatie Eyer, JD, Professor of Law, Rutgers Law SchoolJames Blumstein, LLB, University Distinguished Professor of Constitutional Law and Health Law & Policy, Vanderbilt University Law SchoolLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

It’s Medicare open enrollment season, and in this episode first aired in 2021, we explain why shopping for a new plan is often tougher than it seems.Guests:Lilyan Grossman, Medicare beneficiaryTricia Neuman, ScD, Senior Vice President and Executive Director of the Program on Medicare Policy, Kaiser Family FoundationAmal Trivedi, MD, Professor of Medicine and Health Services, Policy, and Practice, Brown UniversityLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

One of the nation’s leading experts on the Affordable Care Act breaks down its track record and weighs in on the stakes the historic health care law faces in the lead-up to the election.Guest:Larry Levitt, Executive Vice President for Health Policy, KFFLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

The next U.S. president will have to make consequential choices about the Affordable Care Act, prescription drug prices and abortion. We compare the positions of candidates Kamala Harris and Donald Trump on these major health policy issues. (NOTE: This episode has been updated to clarify the number of people who would lose health coverage if Affordable Care Act enhanced subsidies expired.)Guests:Michael Cannon, Director of Health Policy Studies, Cato InstituteEderlina Co, JD, Associate Professor of Law, University of the PacificCynthia Cox, Vice President and Director of Program on the ACA, KFFStacie Dusetzina, PhD, Professor of Health Policy, Vanderbilt University Medical CenterBenedic Ippolito, PhD, Senior Fellow, American Enterprise InstituteRyan Levi, Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Journalist Paula Span, who writes The New Old Age column for the New York Times, shares what she’s learned about how to age well.Guest:Paula Span, reporter and The New Old Age columnist for the New York TimesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

U.S. companies are rethinking their healthcare strategies as costs soar, with many opting to invest in on-site primary care clinics. This trend emphasizes cutting out insurers and bridging access gaps for employees like Lee Sagraves. Personal stories highlight the challenges of managing chronic conditions within a fragmented system. With a proactive approach to employee health, businesses hope to streamline care and reduce expenses, sparking discussions about equity and the future of workplace healthcare.

For decades, the most effective treatment for addiction to methamphetamine or cocaine has been mired in stigma and mostly limited to small research studies. But with deaths involving meth and cocaine on the rise, policymakers across the country are turning to gift cards to fight drug use.This story has been updated to clarify the research on long-term effects of contingency management and the eligibility requirements to deliver contingency management through CalAIM.Credits:Stephen Higgins, PhD, Professor of Psychology and Psychiatry, University of VermontRichard Rawson, PhD, Professor Emeritus, UCLA Department of PsychologyAndrew Dertien, Contingency Management Coordinator, HealthRIGHT 360Bernard GrovesAyesha Appa, MD, Assistant Professor of Medicine, UCSF and San Francisco General HospitalTyler Sadwith, Medicaid Director, California Department of Health Care ServicesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Christine Baeder, President of Apotex USA, Alfred Engelberg, a retired attorney with a focus on the generic pharmaceutical industry, and Jeremy Greene, a professor at Johns Hopkins, dive into the rising costs of life-saving medications. They discuss the emotional toll on patients facing exorbitant prices and the struggles generics face against patent-holding brand companies. The conversation also covers the implications of recent reforms like the Inflation Reduction Act and the ongoing challenges of ensuring affordable medication access for all.

Christine Baeder, President of Apotex USA, Laura Bray, Founder of Angels for Change, and Craig Burton, Senior VP at the Association for Accessible Medicines, delve into the complexities of America's generic drug market. They discuss the hidden costs of low-priced drugs, including quality issues and shortages. A poignant story about the Bray family's struggle with the life-saving drug Vincristine highlights systemic failures and the emotional toll on patients. The conversation stresses the urgent need for reform to ensure drug availability while balancing affordability and quality.

Generic drugs are, in many ways, the unsung hero of America’s health care system, bringing powerful medical innovations within the reach of millions more people. These cheaper copies of brand-name drugs — from pills that stop heart attacks to antibiotics that cure life-threatening infections — save America hundreds of billions of dollars a year. But will affordable, high-quality generic drugs continue to be there when we need them?Some players are abandoning this business while others slash costs by cutting dangerous corners. Shortages of older generic drugs have become the norm, sending doctors scrambling. At the same time, crucial new medicines are proving tougher to copy on the cheap, saddling patients with brand-name prices.Over the course of “Race to the Bottom,” our new three-part podcast series, we’ll explore why this industry that’s so essential to our health is in trouble — and what could change that.In part one, we examine the history of this industry. Forty years ago this month, President Ronald Reagan signed groundbreaking, bipartisan legislation that gave birth to a new drug market. Lawmakers made choices back then that help explain the wild success and also the troubles we see today with generic medicines.Guests:Christine Baeder, MBA, President, Apotex USAAlfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical AssociationLeslie Walker, Senior Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.